Skip to content
Bored Studies
RecruitingPhase 1/Phase 2

A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

Nuevocor Pte. Ltd. · NCT07606274

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1, Phase 2
Target enrollment
21
US sites recruiting
3
Study start
June 16, 2026
Record last updated
August 7, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is designed to evaluate the safety and tolerability of NVC-001 in adults with LMNA-related dilated cardiomyopathy (LMNA-DCM). The study will also assess exploratory measures of efficacy.

Being studied: NVC-001 - Low Dose; NVC-001 - Intermediate Dose; NVC-001 - High Dose

Conditions: LMNA-Related Dilated Cardiomyopathy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Adult ≥18 years old, able to provide informed consent
  • Clinical diagnosis of LMNA-related dilated cardiomyopathy (DCM) with LV systolic dysfunction
  • Pathogenic or likely pathogenic LMNA mutation confirmed by a CLIA-certified/CAP-accredited laboratory
  • NYHA Functional Class I, II, or III
  • LVEF >25% and ≤45% by echocardiography
  • Implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator )CRT-D) implanted >3 months prior to consent

Key Exclusion Criteria

  • Any chronic medical condition that, in the Investigator's opinion, would compromise participant safety or compliance
  • Hospitalization as an inpatient for the following conditions within 3 months prior to signing the ICF: Heart failure, Persistent/refractory ventricular arrhythmia requiring external defibrillation, or multiple/recurrent cardioversion/defibrillation by ICD Indication for, or history of, LV assist device or cardiac transplantation due to end-stage cardiac dysfunction
  • Current or anticipated need for chronic IV inotropic therapy

Recruiting US locations

  • Cedars-Sinai Medical Center

    Los Angeles, CA 90048

    Site contact: Nuevocor Clinical Trial Team · 310-248-8300 · info@nuevocor.com

  • Mayo Clinic

    Rochester, MN 55905

    Site contact: Nuevocor Clinical Trial Team · 507-422-5433 · info@nuevocor.com

  • Houston Methodist Hospital

    Houston, TX 77030

    Site contact: Nuevocor Clinical Trial Team · 281-222-9983 · info@nuevocor.com

A Study With NVC-001 in Patients With LMNA-related Dilated… (NCT07606274) | Bored Studies